Cite
HARVARD Citation
Xing, P. et al. (2018). Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer. Thoracic cancer. 9 (12), pp. 1716-1724. [Online].